China and India are emerging as major players in the life sciences industry. Both countries have a wealth of top talent as well as rapidly-improving resources for the industry. Both countries also constitute important current and potential markets for drugs, devices and diagnostics, and are also projected to be major sources of innovation in the not-too-distant future. This panel will explore the significant opportunities in China and India, in terms not only of expanding operations to both countries, but also in terms of working with innovative companies that originate from China and India.
Moderator:
- David A. Charapp, Special Counsel, Foley & Lardner LLP
讨论嘉宾：
- Stephen A. Bent, Partner, Foley & Lardner LLP
- Friedhelm Blobel, Ph.D., President, CEO, Director, SciClone Pharmaceuticals
- Kim Kamdar, Ph.D., Principal at Domain Associates
- Sanjay Shukla, M.D., M.S., Chief Executive Officer, RxMD
相关见解
2025年12月11日
福莱观点
知识产权组合管理中的反垄断风险与合规策略
本文分析了知识产权组合管理如何在促进创新的同时，也可能带来潜在风险……
2025年12月11日
福莱观点
加州空气资源委员会发布SB 261和SB 253法案的拟议法规
2025年12月9日，加州空气资源委员会（CARB）发布了其针对初始法规的拟议监管文本……
2025年12月11日
创新技术洞察
美国货币监理署发布另一份加密友好型解释性函件：无风险本金加密资产交易的合规性
2025年12月9日，货币监理署（OCC）发布解释性函件1188（IL 1188），确认国家银行作为银行业务的一部分，可从事无风险本金加密资产交易。